Metastatic Triple-Negative Breast Cancer Clinical Trial
Official title:
A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer
The objective is to evaluate the efficacy and safety of Olinvacimab in combination with Pembrolizumab in patients with mTNBC.
After being informed about the study and potential risks, all patients will complete informed consent form in written. During 2 weeks screening period, investigator will evaluate patient eligibility and if it meet with protocol, patient will enrolled. 1 cycle treatment is perform on D1, D8, D15 to inject Olinvacimab and Pembrolizumab, it can be repeated upto 35 cycles. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05831553 -
TIP in Patients Affected by Metastatic TNBC
|
||
| Recruiting |
NCT05570253 -
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04454437 -
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
|
Phase 2 | |
| Recruiting |
NCT05101096 -
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05227664 -
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
| Suspended |
NCT04250818 -
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
|
||
| Completed |
NCT03004183 -
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
|
Phase 2 | |
| Recruiting |
NCT06027268 -
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05746728 -
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05089643 -
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
|
Phase 2 |